Search results
Results from the WOW.Com Content Network
Genzyme (also known as Genzyme Transgenics Corp or GTC Biotherapeutics) was an American biotechnology company based in Cambridge, Massachusetts. From its acquisition in 2011 to 2022 Genzyme operated as a fully owned subsidiary of Sanofi. In 2010, Genzyme was the world's third-largest biotechnology company, employing more than 11,000 people ...
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, ... The following products are listed on the Sanofi Genzyme website.
French drug company Sanofi-Aventis (SNY) has finally made a deal to buy biotech company Genzyme (GENZ) for $20.1 billion, about $74 a share. Genzyme shareholders will get a contingent value right ...
Sanofi , one of the largest pharmaceutical companies on the planet, ... Over the last five years, however, the company has moved into the orphan drug space through the acquisition of Genzyme, ...
In the spring of 2014, Aastrom Bio acquired Sanofi's cell therapy and regenerative medicine business which Sanofi had acquired when purchasing Genzyme in 2011. [1] This transformed Aastrom in several ways: it increased the employee count by 8-fold and provided a revenue stream and products to market, which it had not had before. [1]
It seems that months of contentious merger talks between French pharmaceutical company Sanofi-Aventis (SNY) and U.S. biotech Genzyme (GENZ) have entered the home stretch. Sanofi is expected to ...
Sanofi-Aventis (SNY) CEO Chris Viehbacher (pictured) said in a webcast Wednesday he believes his French pharmaceutical company will eventually buy U.S. biotech company Genzyme (GENZ) at a ...
CAT chose to co-develop the two drugs metelimumab (CAT-192) and fresolimumab with Genzyme. During early development, around 2004, CAT decided to drop development of metelimumab in favour of fresolimumab. [5] In February 2011 Sanofi-Aventis agreed to buy Genzyme for US$20.1 billion. [6]